TY - JOUR
T1 - Olanzapine for the treatment of psychosis in patients with Parkinson’s disease and dementia
AU - Marsh, Laura
AU - Lyketsos, Constantine
AU - Reich, Stephen G.
N1 - Funding Information:
The authors thank Lisette Bunting, R.N., M.Sc.N. for study coordination. This study was supported by Eli Lilly, Inc, the Morris K. Udall Parkinson’ s Disease Research Center of Excellence at Johns Hopkins ( NIH P50-NS-58377 ), and the General Clinical Research Center at Johns Hopkins University School of Medicine ( National Center for Research Resources / NIH M01-RR00052 ).
PY - 2001
Y1 - 2001
N2 - Psychotic symptoms are a common complication in Parkinson’s disease with dementia. The authors conducted an open-label 6-week trial of olanzapine preceded by a placebo lead-in in five subjects with Parkinson’s disease, mild to moderately severe dementia, and psychosis. Four of the subjects terminated the trial early because of worsening motor function, sedation, or paranoia. There was no improvement in psychotic symptoms, and functional abilities declined significantly. Olanzapine appears to be poorly tolerated in patients with Parkinson’s disease, psychotic symptoms, and dementia.
AB - Psychotic symptoms are a common complication in Parkinson’s disease with dementia. The authors conducted an open-label 6-week trial of olanzapine preceded by a placebo lead-in in five subjects with Parkinson’s disease, mild to moderately severe dementia, and psychosis. Four of the subjects terminated the trial early because of worsening motor function, sedation, or paranoia. There was no improvement in psychotic symptoms, and functional abilities declined significantly. Olanzapine appears to be poorly tolerated in patients with Parkinson’s disease, psychotic symptoms, and dementia.
UR - http://www.scopus.com/inward/record.url?scp=0035696459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035696459&partnerID=8YFLogxK
U2 - 10.1176/appi.psy.42.6.477
DO - 10.1176/appi.psy.42.6.477
M3 - Article
C2 - 11815682
AN - SCOPUS:0035696459
SN - 0033-3182
VL - 42
SP - 477
EP - 481
JO - Psychosomatics
JF - Psychosomatics
IS - 6
ER -